Abbott reports positive trial results for Xience V stent
6 May 2010 00:00 in Medical Company Product News
Abbott has published new clinical trial data which demonstrates the effectiveness of its Xience V everolimus-eluting coronary stent system.
The company's medical device was trialled in the recent Spirit IV study among 3,690 patients in order to establish its efficacy compared to the Taxus Express2 paclitaxel-eluting coronary stent system.
It was found that patients using the Abbott system were less likely to suffer an adverse medical event such as a heart attack, blood clot or a repeat procedure than those using the Taxus system.
A follow-up analysis of the trial data showed that use of the Xience V also translated into lower overall medical costs after one year of use.
Dr Gregg Stone, professor of medicine at Columbia University Medical Center and principal investigator of the trial, said: "Based on these results and results from the 1,800-patient Compare study conducted in the Netherlands, the everolimus-eluting stent has set a new standard for patient safety and efficacy."
Last month, Abbott provided a financial update on its performance in the first quarter of 2010, reporting year-on-year sales growth of 10.5 per cent.
Other news stories from 06/05/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency